GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding

被引:187
作者
Airley, RE [1 ]
Loncaster, J
Raleigh, JA
Harris, AL
Davidson, SE
Hunter, RD
West, CML
Stratford, IJ
机构
[1] Liverpool John Moores Univ, Sch Pharm & Chem, Liverpool L3 3AF, Merseyside, England
[2] Christie Hosp, Paterson Inst, Manchester, Lancs, England
[3] Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC USA
[4] John Radcliffe Hosp, Wetherall Inst Mol Med, Oxford OX3 9DU, England
[5] Christie Hosp, Dept Acad Radiat Oncol, Manchester, Lancs, England
[6] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester, Lancs, England
基金
英国医学研究理事会;
关键词
GLUT-1; CAIX; hypoxia; pimonidazole;
D O I
10.1002/ijc.10904
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The presence of hypoxia in tumours results in the overexpression of certain genes, which are controlled via the transcription factor HIF-1. Hypoxic cells are known to be radioresistant and chemoresistant, thus, a reliable surrogate marker of hypoxia is desirable to ensure that treatment may be rationally applied. Recently, the HIF-1-regulated proteins Glut-1 and CAIX were validated as intrinsic markers of hypoxia by comparison with pO(2) measured using oxygen electrodes. We compare the expression of Glut-1 and CAIX with the binding of the bioreductive drug hypoxia marker pimonidazole. Pimonidazole was administered to 42 patients with advanced carcinoma of the cervix, 16 hr before biopsy. Sections of single or multiple biopsies were then immunostained for Glut-1 and CAIX, and the area of staining scored by eye, using a "field-by-field" semi-quantitative averaging system. Using 1 biopsy only, Glut-1 (r = 0.54, p =< 0.001) correlated with the level of pimonidazole binding, and Glut-1 and CAIX expression also correlated significantly (r = 0.40, p = < 0.009). Thus, our study has shown that HIF-1 regulated genes have potential for future use as predictors of the malignant changes mediated by hypoxia, and warrant further investigation as indicators of response to cancer therapy. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:85 / 91
页数:7
相关论文
共 58 条
  • [1] Aboagye EO, 1998, ANTI-CANCER DRUG DES, V13, P703
  • [2] Airley R, 2001, CLIN CANCER RES, V7, P928
  • [3] AIRLEY RE, 2001, THESIS U MANCHESTER, P167
  • [4] Birner P, 2000, CANCER RES, V60, P4693
  • [5] Brizel DM, 1996, CANCER RES, V56, P941
  • [6] Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
    Brizel, DM
    Sibley, GS
    Prosnitz, LR
    Scher, RL
    Dewhirst, MW
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 38 (02): : 285 - 289
  • [7] Cartiana G, 2001, CANCER, V92, P1144
  • [8] MEASUREMENT OF TUMOR HYPOXIA BY INVASIVE AND NONINVASIVE PROCEDURES - A REVIEW OF RECENT CLINICAL-STUDIES
    CHAPMAN, JD
    [J]. RADIOTHERAPY AND ONCOLOGY, 1991, 20 : 13 - 19
  • [9] Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma
    Chia, SK
    Wykoff, CC
    Watson, PH
    Han, C
    Leek, RD
    Pastorek, J
    Gatter, KC
    Ratcliffe, P
    Harris, AL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3660 - 3668
  • [10] Targeting gene expression to hypoxic tumor cells
    Dachs, GU
    Patterson, AV
    Firth, JD
    Ratcliffe, PJ
    Townsend, KMS
    Stratford, IJ
    Harris, AL
    [J]. NATURE MEDICINE, 1997, 3 (05) : 515 - 520